Search
Omacetaxine mepesuccinate
go.drugbank.com/drugs/DB04865ApprovedInvestigationalWithdrawnThen in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. … In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA.
Synonyms: mepesuccinato de omacetaxinaApomorphine
go.drugbank.com/drugs/DB00714ApprovedInvestigationalApomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AntagonistsSynonyms: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diolInfluenza A virus A/Washington/19/2020 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB16727ApprovedWithdrawnVaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus
Pimavanserin
go.drugbank.com/drugs/DB05316ApprovedInvestigational[L48236] Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. … [A232783] It was approved by the FDA in April 2016 for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis thanks to favorable results from a pivotal six-week, randomized
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsIrinotecan
go.drugbank.com/drugs/DB00762ApprovedInvestigationalThis leads to the arrest of the cell cycle in the S-G2 phase and cancer cell death.[A263376] … [A263376] The bis-piperidine side chain in the structure of irinotecan bestows enhanced water solubility.
Products: CLORHIDRATO DE IRINOTECAN TRIHIDRATO 20 MG/MLDarolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
Categories: Androgen Receptor InhibitorsVandetanib
go.drugbank.com/drugs/DB05294ApprovedInvestigationalOn April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
Bismuth subnitrate
go.drugbank.com/drugs/DB13209ApprovedWithdrawnThe use of bismuth substrate as an active ingredient in over-the-counter antacids is approved by the FDA. … Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic
Chlorzoxazone
go.drugbank.com/drugs/DB00356ApprovedIt is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
Sibeprenlimab
go.drugbank.com/drugs/DB18919ApprovedInvestigational[L54633] On November 25, 2025, sibeprenlimab was granted accelerated approval by the FDA to reduce proteinuria in adults with primary IgAN at risk for disease progression.[L54628] … [L54633] APRIL is a member of the tumour necrosis factor superfamily that regulates and modulates activated B cells.